Agenus is a clinical-stage immuno-oncology company focused on developing therapies that engage the body's immune system in fighting cancer and infections. The Company's mission is to broaden the patient populations benefiting from cancer immunotherapy through combination approaches, leveraging a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx).